Common use of JOINT STIPULATION OF DISMISSAL WITH PREJUDICE Clause in Contracts

JOINT STIPULATION OF DISMISSAL WITH PREJUDICE. Pursuant to Massachusetts Rule of Civil Procedure 41(a)(1)(ii), Plaintiff Alnylam Pharmaceuticals, Inc. and Defendant Dicerna Pharmaceuticals, Inc. hereby stipulate that all claims and counterclaims in the above-captioned action be dismissed, with prejudice. Each party shall bear its own costs, expenses, and attorneys’ fees. ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2 Respectfully submitted, ALNYLAM PHARMACEUTICALS, INC. By its attorneys, __________________________________ Xxxx X. Xxxxxxxxx (BBO# 561730) xxxxxxxxxx@xxxxxx.xxx Xxxx X. Xxxxx (BBO# 567727) xxxxxx@xxxxxx.xxx Xxxxxxx X. Xxxxxxx (BBO# 673882) xxxxxxxx@xxxxxx.xxx Xxxxx X. Fails (BBO# 695483) xxxxxx@xxxxxx.xxx Xxxxxx Xxxxxxx-Xxxxxx (BBO# 687068) xxxxxxxxxxxxxx@xxxxxx.xxx XXXXXX XXXX & XXXXXXX LLP Xxx Xxxxxxxxxxxxx Xxxxx Xxxxxx, XX 00000 Tel: 000-000-0000 Fax: 000-000-0000 DICERNA PHARMACEUTICALS, INC. By its attorneys, ___________________________________ Xxxxxxxx X. Xxxxx (BBO# 097800) xxxxxx@xxx-xxx.xxx Xxxxxxx Xxxxxxxxx (BBO# 544209) xxxxxxxxxx@xxx-xxx.xxx Xxxxx X. Xxxxxx (BBO#547703) xxxxxxx@xxx-xxx.xxx XXXXX XXXXXX & XXXXXXXXX LLP Xxx Xxxxxxx Xxxxxx Xxxxxx, XX 00000 Tel: 000-000-0000 Fax: 000-000-0000 Xxxxxxx X. Xxxxxxxxx (BBO # 542156) XXXxxxxxxxx@xxxxxxxxxxx.xxx Xxxxxxx X. Xxxxxxx (BBO # 568517) XXxxxxxx@xxxxxxxxxxx.xxx Xxxxxxx X. Xxxxxxx (BBO # 679720) xxxxxxxx@xxxxxxxxxxx.xxx XXXXX XXXXXX LLP 000 Xxxx Xxxxxx, Xxxxx 0000 Xxxxxx, XX 00000 Telephone: 000.000.0000 Dated: April __18, 2018 ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2 UNITED STATES DISTRICT COURT DISTRICT OF MASSACHUSETTS

JOINT STIPULATION OF DISMISSAL WITH PREJUDICE. Pursuant to Massachusetts Federal Rule of Civil Procedure 41(a)(1)(ii41(a)(1)(A)(ii), Plaintiff Alnylam Dicerna Pharmaceuticals, Inc. and Defendant Dicerna Alnylam Pharmaceuticals, Inc. hereby stipulate that all claims and counterclaims in the above-captioned action be dismissed, with prejudice. Each party shall bear its own costs, expenses, and attorneys’ fees. ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2 Respectfully submitted, ALNYLAM PHARMACEUTICALS, INC. By its attorneys, __________________________________ Xxxx X. Xxxxxxxxx (BBO# 561730) xxxxxxxxxx@xxxxxx.xxx Xxxx X. Xxxxx (BBO# 567727) xxxxxx@xxxxxx.xxx Xxxxxxx X. Xxxxxxx (BBO# 673882) xxxxxxxx@xxxxxx.xxx Xxxxx X. Fails (BBO# 695483) xxxxxx@xxxxxx.xxx Xxxxxx Xxxxxxx-Xxxxxx (BBO# 687068) xxxxxxxxxxxxxx@xxxxxx.xxx XXXXXX XXXX & XXXXXXX LLP Xxx Xxxxxxxxxxxxx Xxxxx Xxxxxx, XX 00000 Tel: 000-000-0000 Fax: 000-000-0000 DICERNA PHARMACEUTICALS, INC. By its attorneys, ___________________________________ Xxxxxxxx X. Xxxxx (BBO# 097800) xxxxxx@xxx-xxx.xxx Xxxxxxx Xxxxxxxxx (BBO# 544209) xxxxxxxxxx@xxx-xxx.xxx Xxxxx X. Xxxxxx (BBO#547703) xxxxxxx@xxx-xxx.xxx XXXXX XXXXXX & XXXXXXXXX LLP Xxx Xxxxxxx Xxxxxx Xxxxxx, XX 00000 Tel: 000-000-0000 Fax: 000-000-0000 Xxxxxxx X. Xxxxxxxxx (BBO # 542156) XXXxxxxxxxx@xxxxxxxxxxx.xxx Xxxxxxx X. Xxxxxxx (BBO # 568517) XXxxxxxx@xxxxxxxxxxx.xxx Xxxxxxx X. Xxxxxxx (BBO # 679720) xxxxxxxx@xxxxxxxxxxx.xxx XXXXX XXXXXX LLP 000 Xxxx Xxxxxx, Xxxxx 0000 Xxxxxx, XX 00000 Telephone: 000.000.0000 Dated: April __18, 2018 ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2 UNITED STATES DISTRICT COURT DISTRICT OF MASSACHUSETTS2018

JOINT STIPULATION OF DISMISSAL WITH PREJUDICE. Pursuant to Massachusetts Federal Rule of Civil Procedure 41(a)(1)(ii)41, Plaintiff Alnylam Pharmaceuticalsthe parties, Inc. plaintiff Fargo Electronics, Inc., and Defendant Dicerna Pharmaceuticalsdefendants Toppan Printing Co., Inc. Ltd., and Trans Digital Technologies, Corp., by their respective undersigned counsel, hereby stipulate that all claims and counterclaims in the above-captioned action be dismissed, with prejudiceto dismiss this lawsuit WITH PREJUDICE. Each party shall bear its own costsattorney’s fees and costs in connection with this lawsuit. Dated: May 17, expenses, and attorneys’ fees. ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2 2005 Respectfully submitted, ALNYLAM PHARMACEUTICALSRespectfully submitted, INC. By its attorneys, __________________________________ Xxxx X. Xxxxxxxxx (BBO# 561730) xxxxxxxxxx@xxxxxx.xxx Xxxx X. Xxxxx (BBO# 567727) xxxxxx@xxxxxx.xxx Xxxxxxx X. Xxxxxxx (BBO# 673882) xxxxxxxx@xxxxxx.xxx Xxxxx X. Fails (BBO# 695483) xxxxxx@xxxxxx.xxx Xxxxxx Xxxxxxx-Xxxxxx (BBO# 687068) xxxxxxxxxxxxxx@xxxxxx.xxx , Esq. ROBINS, KAPLAN, XXXXXX XXXX & XXXXXXX LLP Xxx Xxxxxxxxxxxxx XXXXXX L.L.P. 0000 X Xxxxxx, XX, Xxxxx Xxxxxx0000 Xxxxxxxxxx, XX 00000 Tel: (000-) 000-0000 Fax: Xxxx X. Xxxxxx Xxxxxx X. Xxxx, Xx. XXXXXX, XXXXXXX & XXXXXXX L.L.P. 0000 Xxxxxxxxxxxx Xxxxxx, XX, Xxxxx 000 Xxxxxxxxxx, XX 00000 (000-) 000-0000 DICERNA PHARMACEUTICALSand and Xxxxx Xxxxxx Xxxxxxx Xxxxxx Xxxx Xxxxxxx ROBINS, INC. By its attorneysKAPLAN, ___________________________________ Xxxxxxxx X. Xxxxx (BBO# 097800) xxxxxx@xxx-xxx.xxx Xxxxxxx Xxxxxxxxx (BBO# 544209) xxxxxxxxxx@xxx-xxx.xxx Xxxxx X. Xxxxxx (BBO#547703) xxxxxxx@xxx-xxx.xxx XXXXX XXXXXX & XXXXXXXXX LLP Xxx Xxxxxxx Xxxxxx Xxxxxx, XX 00000 Tel: 000-000-0000 Fax: 000-000-0000 Xxxxxxx X. Xxxxxxxxx (BBO # 542156) XXXxxxxxxxx@xxxxxxxxxxx.xxx Xxxxxxx X. Xxxxxxx (BBO # 568517) XXxxxxxx@xxxxxxxxxxx.xxx Xxxxxxx X. Xxxxxxx (BBO # 679720) xxxxxxxx@xxxxxxxxxxx.xxx XXXXX XXXXXX LLP L.L.P. 000 Xxxx XxxxxxXxxxxxxxxx Xxx, Xxxxx 0000 Xxxxxx, XX 00000-0000 (000) 000-0000 Counsel for FARGO ELECTRONICS, INC. Xxxxxx Xxxx III Xxxx Xxxxxxxx Xxxxxx XXXXXX, XXXXXXX & XXXXXXX L.L.P. Xxx Xxxxxxxx Xxxxx, Xxxxx 000 Xxx Xxxxxxxxx, XX 00000 Telephone: 000.000.0000 Dated: April __18(000) 000-0000 Counsel for TOPPAN PRINTING CO., 2018 ***Text Omitted LTD. Respectfully submitted, Xxxxx X. Xxxxxxxx XXXXXXX LLP 000 0xx Xxxxxx, XX Xxxxxxxxxx, XX 00000-0000 (000) 000-0000 and Filed Separately with the Securities and Xxxxxx X. Xxxxx, Xx. Xxxx X. Xxxxxxxxx Xxxx X. Xxxxxxx, Esq. XXXXXX, XXXX & XXXXXXX Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4Place 00 Xxxxx Xxxxxx Xxxxxx, XX 00000 (000) and 240.24b-2 UNITED STATES DISTRICT COURT DISTRICT OF MASSACHUSETTS000-0000 Counsel for TRANS DIGITAL TECHNOLOGIES, CORP.

JOINT STIPULATION OF DISMISSAL WITH PREJUDICE. Pursuant IT IS HEREBY STIPULATED by and among the parties to Massachusetts Rule of Civil Procedure 41(a)(1)(ii), Plaintiff Alnylam Pharmaceuticals, Inc. and Defendant Dicerna Pharmaceuticals, Inc. hereby stipulate this action through their counsel that all claims and counterclaims in the above-captioned action (including without limitation all Claims and Counterclaims asserted and requests for Relief in this action) be dismissed, and hereby are dismissed in their entirety with prejudice. prejudice pursuant to Federal Rule of Civil Procedure 41(a)(1) Each party shall bear its own costs, expenses, costs and attorneys’ feesfees in this action. ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(420 Exhibit D (continued) and 240.24b-2 Respectfully submitted, ALNYLAM PHARMACEUTICALS, INC. By its attorneys, __________________________________ By: Xxxxx X. Xxxx (SR 5803) Xxxxx X. Xxxxxxxxx Xxxxxx (BBO# 561730BS 7914) xxxxxxxxxx@xxxxxx.xxx Xxxx X. Xxxxx (BBO# 567727) xxxxxx@xxxxxx.xxx Xxxxxxx X. Xxxxxxx (BBO# 673882GS 6416) xxxxxxxx@xxxxxx.xxx Xxxxx Xxxxxx X. Fails Xxxxxxxx (BBO# 695483RS 1921) xxxxxx@xxxxxx.xxx FITZPATRICK, CELLA, XXXXXX & XXXXXX 0000 Xxxxxx Xxxxxxx-Xxxxxx (BBO# 687068) xxxxxxxxxxxxxx@xxxxxx.xxx XXXXXX XXXX & XXXXXXX LLP xx xxx Xxxxxxxx Xxx Xxxxxxxxxxxxx Xxxxx XxxxxxXxxx, XX 00000 Tel: (000-) 000-0000 Fax: (000-) 000-0000 DICERNA PHARMACEUTICALSxxxxx@xxxx.xxx; xxxxxxx@xxxx.xxx; xxxxxxxx@xxxx.xxx; xxxxxxxxx@xxxx.xxx Attorneys for Regeneron Pharmaceuticals, INCInc., Sanofi-Aventis US. By its attorneysLLC, ___________________________________ Xxxxxxxx and Sanofi Aventis US. Inc. Xxxxxx Xxx (Pro Hac Vice) Xxxxx X. Xxxxxxx (Pro Hac Vice) Xxxxx X. Xxxx (Pro Hac Vice) Xxxx Xxxxx (BBO# 097800Pro Hac Vice) xxxxxx@xxx-xxx.xxx IRELL & XXXXXXX LLP 0000 Xxxxxx xx xxx Xxxxx, Xxxxx 000 Xxx Xxxxxxx, XX 00000-0000 Tel: (000) 000-0000 Fax: (000) 000-0000 xxxx@xxxxx.xxx; xxxxxxxx@xxxxx.xxx; xxxxx@xxxxx.xxx; xxxxxx@xxxxx.xxx Xxxxxxx Xxxxxxxxx X. Xxxxxxxx (BBO# 544209SR34 70) xxxxxxxxxx@xxx-xxx.xxx SKADDEN, ARPS, SLATE, XXXXXXX & XXXX LLP Xxxx Xxxxx X. Xxxxxx (BBO#547703) xxxxxxx@xxx-xxx.xxx XXXXX XXXXXX & XXXXXXXXX LLP Xxx Xxxxxxx Xxxxxx XxxxxxXxxx, XX 00000 Tel: (000-) 000-0000 Fax: (000-) 000-0000 Xxxxxxx.Xxxxxxxx@xxxxxxx.xxx Attorneys for Regeneron Pharmaceuticals, Inc. By: Xxxxxxx X. Xxxxxxxxx (BBO # 542156) XXXxxxxxxxx@xxxxxxxxxxx.xxx Xxxxxxx Xxxxx Xxxxx X. Xxxxxxx (BBO # 568517) XXxxxxxx@xxxxxxxxxxx.xxx Xxxxxxx X. Xxxxxxx (BBO # 679720) xxxxxxxx@xxxxxxxxxxx.xxx XXXXX XXXXXX Xxxxxx XXXX, WEISS, RIFKIND, XXXXXXX & XXXXXXXX LLP 000 Xxxx Xxxxxx, Xxxxx 0000 XxxxxxX Xxxxxx XX Xxxxxxxxxx, XX 00000 TelephoneTel: 000.000.0000 (000) 000-0000 Fax: (000) 000-0000 xxxxxx@xxxxxxxxx.xxx xxxxxxx@xxxxxxxxx.xxx Xxxx Xxxx Xxxxx Xxxx X. Xxxxx XXXX, WEISS, RIFKIND, XXXXXXX & XXXXXXXX LLP 1200 Xxxxxx xx xxx Xxxxxxxx Xxx Xxxx, XX 00000-0000 Xel: (000) 000-0000 Fax: (000) 000-0000 estone @xxxxxxxxx.xxx xxxxxx@xxxxxxxxx.xxx Xxxxxxxx Xxxxxx Xxxxx Xxxxxxxx XXXXX XXXXX LLP 30 Xxxxxxxxxxx Xxxxxx Xxx Xxxx, XX 00000 Xel: (000) 000-0000 Fax: (000) 000-0000 xxxxxxxx. xxxxxx@bakerbotts. com xxxxx.xxxxxxxx@xxxxxxxxxx.xxx Attorneys for Genentech, Inc. Exhibit D (continued) SO ORDERED: U.S.D.J. Dated: April __18, 2018 ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2 UNITED STATES DISTRICT COURT DISTRICT OF MASSACHUSETTS: